How was he treated for advanced colon cancer?

时间：2026-04-24　人气：

If you cannot understand the subsequent professional description, you can finish reading this text in two minutes

Overview of the Disease

In May 2020, Mr. Yang experienced discomfort in his left lower abdomen without any apparent cause, which later resolved spontaneously. Abdominal CT scan revealed a mass in the descending colon and a liver lesion, suggesting metastasis. PET-CT scan showed thickening of the wall at the junction of the descending and sigmoid colon, narrowing of the lumen, serosal invasion, and surrounding lymph node metastasis; increased metabolic activity in liver S8, also suggesting metastasis. Colonoscopy revealed an ulcerative mass growing circumferentially, making it impossible for the endoscope to pass through. Pathology: moderately differentiated adenocarcinoma.

After being diagnosed with colon cancer, Mr. Yang underwent partial hepatectomy and radical resection of the sigmoid colon in June 2020. Postoperative pathology: 1. (Sigmoid colon): ulcerative moderately differentiated adenocarcinoma, with cancer invading the subserosal fibrous adipose tissue; visible vascular and neural invasion; pericolic lymph node metastasis (4/21), with cancer invading beyond the lymph node capsule. Moderately differentiated adenocarcinoma was found in the resected liver tissue from S8, consistent with liver metastasis from intestinal cancer; no cancer was found at the resection margin; tumor pathological stage: pT3N2aM1.

Postoperative gene testing results: KRAS mutation p.G12A, APC mutation, MSS, TMB 4.49muts/Mb, NRAS and BRAF wild-type.

Postoperative abdominal CT scan: multiple small lymph nodes newly found in the mesentery. In July 2020, Mr. Yang underwent four cycles of XELOX chemotherapy.

After surgery, Mr. Yang again found multiple small lymph nodes newly found in the mesentery. On July 6, 2020, he underwent XELOX chemotherapy. Post-chemotherapy CT scan: multiple small lymph nodes in the mesentery remained unchanged, suggesting metastasis.

Section

small

Knowledge

Shi

KRAS gene mutation

KRAS is a downstream gene of the EGFR signaling pathway mentioned in previous articles. Mutations in the KRAS gene keep the EGFR signaling pathway activated, continuously stimulating cell growth, development, and proliferation, leading to malignant transformation of cells. The results of genetic testing can guide subsequent treatment to a certain extent.

Mr. Yang completed surgery and postoperative chemotherapy. Due to late detection, liver metastases had already occurred, and although they were removed, there may still be residual cancer cells in the body that cannot be detected. After extensive research, Mr. Yang and his family learned about Professor Zhang Minghui's NKT technology at Tsinghua University School of Medicine through a friend's recommendation, and carefully reviewed the demonstrated cases of NKT cell therapy. They particularly hope to try it to reduce the risk of tumor recurrence and delay the time of recurrence/metastasis.

After reviewing Mr. Yang's medical records, Professor Zhang Minghui made the following analysis and judgment:

1. When the patient discovered the tumor, it had already metastasized, and the stage was relatively late. Pathology revealed risk factors such as vascular cancer thrombus and nerve invasion.

2. Colon malignancies are relatively special, and even if liver metastasis occurs, there is still a chance for surgery to perform radical resection to remove both the primary lesion and metastatic lesions, with a better prognosis compared to other metastatic tumors.

3. The patient underwent radical resection and postoperative chemotherapy, completing the basic conventional treatment plan. However, many patients often cannot completely eradicate the tumor through surgery and chemotherapy alone, and there is still a risk of metastatic recurrence.

4. NKT therapy utilizes powerful immune cells to kill tumor cells that may remain in the body and are undetectable, with essentially no side effects. On the basis of completing conventional treatment, NKT therapy can effectively reduce the risk of tumor recurrence and delay the time of recurrence/metastasis. From December 2020 to October 2022, Mr. Yang completed a total of 36 treatment sessions and underwent long-term follow-up. During this period, multiple examinations revealed no clear signs of tumor recurrence

Imaging

Swelling Standard

In May 2020, CEA increased, but returned to normal range during the follow-up examination in June 2020, and no abnormalities were found during subsequent regular examinations; CA19-9remained within the normal range during regular monitoring.

Quality of Life

Mr. Yang's quality of life has been greatly improved. His mental state is excellent, and he feels more energetic and vigorous when doing things than before. He has returned to his pre-illness state, and his normal life and work have not been affected by the disease.

Conclusion Theory

Mr. Yang achieved the expected results after adopting the NKT cell therapy method. After more than a year, the latest assessment result remains stable with no progression observed. Immunotherapy is considered one of the most promising directions in tumor treatment, and Mr. Yang's case serves as a good illustration of this point.

Popular science knowledge is provided for reference only, and individual patients should follow clinical medical advice.

NKT classic case review

Click on the image

to view

上一篇：直肠癌未行手术治疗，现5年了患者状况如何？

下一篇：结合案例，带你了解结肠癌早期症状

About Lehe

New Medical Services

Oncology Clinical Research

Chronic Disease Research

Contact Us

Contact Us

How was he treated for advanced colon cancer?

Contact Us